abstract: Clinical trials testing infertility treatments often do not report on the major outcomes of interest to patients and clinicians and the public (such as live birth) nor on the harms, including maternal risks during pregnancy and fetal anomalies. This is complicated by the multiple participants in infertility trials which may include a woman (mother), a man (father), and result in a third individual if successful, their offspring (child), who is also the desired outcome of treatment. The primary outcome of interest and many adverse events occur after cessation of infertility treatment and during pregnancy and the puerperium, which create a unique burden of follow-up for clinical trial investigators and participants. In 2013, because of the inconsistencies in trial reporting and the unique aspects of infertility trials not adequately addressed by existing Consolidated Standards of Reporting Trials (CONSORT) statements, we convened a consensus conference in Harbin, China, with the aim of planning modifications to the CONSORT checklist to improve the quality of reporting of clinical trials testing infertility treatment. The consensus group recommended that the preferred primary outcome of all infertility trials is live birth (defined as any delivery of a live infant ≥20 weeks gestations) or cumulative live birth, defined as the live birth per women over a defined time period (or number of treatment cycles). In addition, harms to all participants should be systematically collected and reported, including during the intervention, any resulting pregnancy, and during the neonatal period. Routine information should be collected and reported on both male and female participants in the trial. We propose to track the change in quality that these guidelines may produce in published trials testing infertility treatments. Our ultimate goal is to increase the transparency of benefits and risks of infertility treatments to provide better medical care to affected individuals and couples.
Introduction
Thus at a minimum, a successful outcome involves three individuals, one of whom does not exist at the start of the trial. This creates uncertainty on what to report on whom.
There is a natural time lag between the end of an episode of infertility treatment and the birth of an infant, which may result in loss to follow-up, primarily because obstetric and infant care is delivered by other providers. This contributes to incomplete reporting of outcomes and harms of treatment. Clinical trials in infertility frequently do not report items of critical importance regarding efficacy, such as ongoing pregnancy (Clarke et al., 2010; Dapuzzo et al., 2011) or live birth of a healthy infant, arguably the most important event (Min et al., 2004) . Rather they often focus on surrogate outcomes of varying clinical importance, such as ovulation rates, number of oocytes retrieved, embryo fertilization and implantation rates (Legro and Myers, 2004; Johnson, 2006) . Reports on the safety of interventions include risks to females and males during infertility treatment, to the mother during the subsequent pregnancy and to fetuses and infants, including preterm delivery. In addition, fetal anomaly rates, developmental delays and other adverse infant outcomes (Wennerholm and Bergh, 2004) are variably reported or not mentioned at all (Dapuzzo et al., 2011) . This creates uncertainty on how long to report outcomes and harms in humans after completion of the infertility intervention (Vail and Gardener, 2003) .
We sought to improve the quality of reporting of infertility trials by convening an expert conference of key stakeholders in the conduct and publishing of infertility trials to consider how to improve publication by including items of vital interest to infertile couples, clinicians and the public. We achieved a consensus on these items and drafted changes to the 22-item checklist of the CONSORT statement to provide guidance on what to collect on whom and for how long in infertility trials. Such guidance has already been achieved for other specialized types of clinical trials (Gagnier et al., 2006; Piaggio et al., 2006; Boutron et al., 2008; MacPherson et al., 2010) .
Methods
We developed these changes in three phases, including a pre-meeting planning phase, the meeting itself and a post meeting review of results based on previous extensions to the CONSORT checklist (Gagnier et al., 2006; Boutron et al., 2008; MacPherson et al., 2010) , and published guidance for implementing such change . In planning for the meeting, we sought to assemble a representative group of experienced investigators in trials of infertility treatments as well as the editors of the leading journals that publish fertility trials, Fertility & Sterility and Human Reproduction, to participate in the meeting. With the input of the Scientific Committee we framed topics of relevance to clinical trials of infertility and most invited participants were asked to prepare a lecture in their field of expertise for the open part of the meeting.
Invited participants included experts in reproductive medicine and reproductive endocrinology, andrology, maternal-fetal medicine, neonatology, traditional Chinese medicine, biostatistics and clinical trial study design, data safety monitoring and journal Editors. Invited participants (N ¼ 25) were queried by email prior to the meeting about their suggested changes to the CONSORT checklist. We received comments from 11 individuals in the following distribution according to the checklist item (in descending order of frequency): Results (22 comments), Intervention (10 comments), Outcomes (9 comments), Introduction (6 comments), Title and Abstract (5 comments), Discussion (5 comments), Participants (3 comments), Sample size (4 comments), Blinding (2 comments), Statistical Methods (4 comments), Randomization (3 comments), Other information (3 comments) and Methods (2 comments).
The meeting was designed as a one and a half day open meeting with public lectures framing issues in infertility trials followed by a one and a half day closed meeting among the invited participants to achieve consensus. The Scientific Committee divided the three half day closed sessions into discussions about: (i) Main outcomes of infertility trials; (ii) Adverse events in infertility trials; and (iii) Participant issues in infertility trials. Each session was led by two members of the Scientific Committee and each suggested modification was discussed until consensus was achieved with a total of 20 modifications finally (N ¼ 20) . Representatives from the U.S. National Institutes of Health of the United States were unable to attend the meeting due to budgetary sequestration and one representative from China was unable to attend the closed meeting. After the meeting we circulated a draft summary report to all participants to ensure that it accurately represented the deliberations and decisions of the consensus group.
Results
The group recommended a revision to eight items in the CONSORT Checklist (Table I ). The full amended CONSORT checklist is shown in Table II . Several of the revisions had multiple components. The item that generated the most discussion was the optimal primary outcome of an infertility trial with options ranging from an ongoing viable intrauterine pregnancy to a healthy child with normal development. The group decided that trials testing infertility treatments should report as the primary outcome: live birth with a definition based on gestational age (i.e. ≥20 weeks) reflecting the World Health Organization definition of live birth as a fetus exiting the body displaying signs of life such as movement, breathing or heartbeat (World Health Organization, 1993) . While the group acknowledged that the ultimate goal of an infertility trial is a healthy baby who develops normally, and that ideally this outcome should always be reported, the difficulties in tracking this outcome and clearly defining it precluded it as a choice for the primary outcome of an infertility trial. Because most infertility trials involve multiple treatment cycles, cumulative live birth rates should also be reported in this context. This discussion also overlapped with the potential harms of infertility treatment. The group recommended more complete tracking of potential harms of infertility treatment including ovarian hyperstimulation syndrome (OHSS) and multiple pregnancy as well as adverse events during pregnancy and the neonatal/infancy period, including any fetal anomalies. To aid reporting of such events, the group developed a table of key potential harms to collect and report (Table III) .
Discussion
We developed recommendations for modifications of the CONSORT checklist to improve the quality of reporting of trials of infertility treatments. Our suggested revisions were designed to aid transparency of trials, including requiring more complete characterization of the participants in an infertility trial, providing some uniform measure of pregnancy outcome (we chose live birth), and accounting for the major harms and risks to the participants in an infertility trial as well as the resulting fetus (es)/infant (s). While we see this checklist primarily of relevance to larger pragmatic randomized infertility trials, we believe it is also applicable to smaller randomized or prospective non-randomized or single intervention trials which pilot newer treatments. All such trials must be Eligibility criteria for participants Characterize how infertility factors in male and female participants were evaluated, describe the definitions used, any preconception screening, and on which participants informed consent was obtained.
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were actually administered
State the duration of the intervention noting when the treatment started and concluded. State the temporal relation of the intervention with randomization and pregnancy.
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed
Clearly define the primary outcome. Reporting live birth (defined as a delivery ≥20 weeks gestation) is preferred (including gestational age, birthweight and sex of infant). When .1 cycle occurs or frozen embryos are transferred, the preferred outcome is cumulative live birth per woman. Secondary pregnancy outcomes that merit reporting are serum pregnancy, ongoing pregnancy (≥12 weeks), multiple pregnancy and an accounting of all pregnancy losses. Both male and female outcomes, other than live birth, could be the primary outcome and should be justified. When live birth is not the primary end-point and infertility treatment is given (for example, embryos are transferred), live birth should still be reported.
Results

Participant flow 13a
For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analyzed for the primary outcome Report the numbers of couples who were screened and eligible Continued registered with a clinical trial registry prior to enrolling the first patient, so it is possible to a priori capture these outcomes in the trial design. It is incumbent on all researchers to capture harms and pregnancy outcomes even in these smaller trials because they may serve as the basis for larger multi-center trials or become incorporated in systematic reviews. Incomplete reporting contributes to gaps in evidence-based infertility treatment (Johnson et al., 2003) . A longer more detailed rationale paper of the suggested changes (The Harbin Consensus Conference Workshop Group, 2014, see Supplementary data for details) includes examples of ideal reporting and serves as an Explanation and Elaboration paper . We will scrutinize published trials of infertility treatments subsequently to determine if our modifications to the CONSORT checklist have improved the quality of reported information related to participants, outcomes and harms of treatment. We also plan to re-convene a meeting within the next 5 years to formally review our experience and the need for further modifications or revisions to the CONSORT checklist. In the interim, we hope that medical journals will endorse their use, clinical researchers will incorporate the collection of these data into their trial design and reporting, and that ultimately medical care will improve from the increased transparency of the risk/benefit ratio of infertility treatments (Johnson et al., 2003) .
Supplementary data
Supplementary data are available at http://humrep.oxfordjournals.org/.
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